news
Press release
 
April 19, 2016
Dr. Martin Leon Accepts Executive Advisor Role with Corindus Vascular Robotics as External Consultant

Dr. Leon's experience and knowledge will be crucial to the execution of the company's roadmap

WALTHAM, MA - April 19, 2016Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that Martin Leon, MD, one of the preeminent thought leaders in the field of interventional cardiology, has joined the company as an external consultant and executive advisor.

Martin Leon, MDDr. Leon is the Director of the Center for Interventional Vascular Therapy, Director of the Cardiac Catheterization Laboratories, and an Executive board member of the New York-Presbyterian Heart Valve Center. Dr. Leon is a practicing interventional cardiologist at New York-Presbyterian Hospital in New York City and is the founder and Chairman Emeritus of the Cardiovascular Research Foundation (CRF). Dr. Leon has been a principal driver in the emergence and success of many technologies, including drug-eluting stents and transcatheter aortic valve replacement (TAVR).

Dr. Leon has served as principal investigator for over 50 clinical trials that have helped shape the field of interventional cardiovascular medicine, has co-authored over 1,550 publications, has performed over 10,000 interventional procedures, and has had a major impact as a thought-leader and innovator in expanding the sub-specialty of interventional cardiovascular devices and drug therapies. He is Director and founder of Transcatheter Cardiovascular Therapeutics, the world's premier interventional cardiovascular meeting, which recently celebrated its 26th anniversary.

"Throughout my years as a practicing interventional cardiologist, I have had an opportunity to play a role in the development of a number of critical technologies in the field, which is why I am excited about the opportunity to be a part of the growing field of robotics," said Dr. Leon. "I look forward to working with Mark Toland and the rest of the Corindus team in continuing to drive the future of robotics in the cath lab and helping to establish it as another significant improvement in patient care."

As an external consultant and executive advisor for Corindus, Dr. Leon will advise the Corindus executive team on technology development, clinical research strategy, and growth strategy including partnerships and alliances. He also will continue in his role as a practicing interventional cardiologist and a leader of CRF.

In making the announcement, Corindus President and CEO Mark Toland said, "We are extremely pleased and honored to formalize our relationship with Dr. Leon. Corindus values the tremendous experience and perspective he brings to his role as an advisor with our company and we look forward to his many contributions to our continued growth. We view the development of robust partnerships with thought leaders such as Dr. Leon as a key part of our future growth strategy."

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window
Thank you for subscribing to our newsletter. You will now receive email updates from Corindus.